Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary endpoint.
Nick Paul Taylor
Jun 9, 2026 5:22am
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer
Jun 9, 2026 4:41am
How AI is reshaping biopharma decision-making
Brought to you by
Clarivate
City lays foundation for RNAi renaissance with nearly $100M
Jun 8, 2026 4:00pm
Managing complexity across biopharma modalities
Brought to you by
SK Pharmteco
Treeline sees path to public markets via reverse merger
Jun 8, 2026 10:37am
